Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
|CEO||Rick E. Winningham M.B.A.|
Ugland House, South Church Street
George Town, Grand Cayman, E9 KY1-1104
|Fiscal Year||January - December|
|Rick E. Winningham M.B.A.||Chairman and Chief Executive Officer|
|Andrew Asa Hindman M.B.A||Senior Vice President and Chief Financial Officer|
|Rhonda F. Farnum||Chief Business Officer and Senior Vice President of Commercial and Medical Affairs|
|Dr. Richard A. Graham Ph.D.||Senior Vice President of Research & Development|
|Gail B. Cohen||Vice President of Corporate Communications and Investor Relations|
|Brett A. Grimaud Esq.||Senior Vice President, General Counsel and Secretary|
|Stacy L. Pryce||Senior Vice President and Chief Strategy Officer|
Latest SEC Filings
|Nov 14, 2023||144||Filing|
|Nov 9, 2023||10-Q||Quarterly Report|
|Nov 7, 2023||8-K||Current Report|
|Oct 30, 2023||8-K||Current Report|
|Oct 16, 2023||144||Filing|
|Sep 14, 2023||144||Filing|
|Sep 12, 2023||8-K||Current Report|
|Aug 14, 2023||SC 13D/A||[Amend] General statement of acquisition of beneficial ownership|
|Aug 11, 2023||144||Filing|
|Aug 9, 2023||10-Q||Quarterly Report|